Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Xoma Royalty Corporation (XOMA)

Xoma Royalty Corporation (XOMA)
19.44 x 1 19.97 x 12
Post-market by (Cboe BZX)
19.97 +0.27 (+1.37%) 04/11/25 [NASDAQ]
19.44 x 1 19.97 x 12
Post-market 19.97 unch (unch) 16:02 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
19.38
Day High
20.38
Open 19.61
Previous Close 19.70 19.70
Volume 15,000 15,000
Avg Vol 29,440 29,440
Stochastic %K 44.88% 44.88%
Weighted Alpha -30.49 -30.49
5-Day Change +0.53 (+2.73%) +0.53 (+2.73%)
52-Week Range 18.35 - 35.00 18.35 - 35.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 238,701
  • Shares Outstanding, K 11,953
  • Annual Sales, $ 28,490 K
  • Annual Income, $ -13,820 K
  • EBIT $ -40 M
  • EBITDA $ -40 M
  • 60-Month Beta 1.00
  • Price/Sales 8.27
  • Price/Cash Flow N/A
  • Price/Book 2.84

Options Overview Details

View History
  • Implied Volatility 107.76% ( -0.76%)
  • Historical Volatility 40.85%
  • IV Percentile 98%
  • IV Rank 95.53%
  • IV High 110.71% on 04/01/25
  • IV Low 44.82% on 06/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 21
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 38
  • Open Int (30-Day) 38

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.26
  • Number of Estimates 3
  • High Estimate -0.20
  • Low Estimate -0.31
  • Prior Year -0.86
  • Growth Rate Est. (year over year) +69.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.35 +8.82%
on 04/07/25
Period Open: 20.50
21.92 -8.90%
on 04/09/25
-0.53 (-2.59%)
since 03/11/25
3-Month
18.35 +8.82%
on 04/07/25
Period Open: 25.18
29.02 -31.19%
on 01/15/25
-5.21 (-20.69%)
since 01/10/25
52-Week
18.35 +8.82%
on 04/07/25
Period Open: 26.20
35.00 -42.94%
on 11/27/24
-6.23 (-23.78%)
since 04/11/24

Most Recent Stories

More News
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

XOMA : 19.97 (+1.37%)
XOMAP : 25.52 (-1.43%)
XOMAO : 25.20 (-0.40%)
XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA : 19.97 (+1.37%)
XOMAP : 25.52 (-1.43%)
XOMAO : 25.20 (-0.40%)
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

XOMA : 19.97 (+1.37%)
XOMAP : 25.52 (-1.43%)
XOMAO : 25.20 (-0.40%)
Bank Rate Decision Due Next Week

U.S. Monday Featured Earnings Oracle Corporation (NYSE:ORCL) (Q3) EPS of $1.18, compared ...

BEKE : 18.44 (+1.99%)
XOMA : 19.97 (+1.37%)
ULTA : 361.46 (+1.83%)
EVEX : 3.61 (+5.56%)
MTN : 142.59 (+2.00%)
CCI : 96.67 (+1.59%)
ORCL : 132.35 (-0.75%)
DKS : 185.93 (-2.15%)
ENGH.TO : 23.90 (+1.27%)
BNTX : 96.52 (+3.65%)
GOGO : 7.08 (-0.42%)
FERG : 164.73 (+1.84%)
XOMA Royalty to Present at Investor Conferences in March

XOMA : 19.97 (+1.37%)
XOMAP : 25.52 (-1.43%)
XOMAO : 25.20 (-0.40%)
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

XOMA : 19.97 (+1.37%)
XOMAP : 25.52 (-1.43%)
XOMAO : 25.20 (-0.40%)
XOMA Royalty Corporation Announces Cash Dividends for Series A and Series B Preferred Stock

XOMA Royalty Corporation announces upcoming cash dividends for Series A and B Preferred Stock, payable January 15, 2025.Quiver AI SummaryXOMA Royalty Corporation has announced that its Board of Directors...

XOMA : 19.97 (+1.37%)
XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA : 19.97 (+1.37%)
XOMAP : 25.52 (-1.43%)
XOMAO : 25.20 (-0.40%)
XOMA Royalty Acquires Pulmokine, Adding Seralutinib as its Seventh Phase 3 Royalty Asset

XOMA Royalty acquires seralutinib, enhancing its Phase 3 royalty assets targeting pulmonary arterial hypertension.Quiver AI SummaryXOMA Royalty Corporation has acquired an economic interest in seralutinib,...

XOMA : 19.97 (+1.37%)
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

XOMA : 19.97 (+1.37%)
XOMAP : 25.52 (-1.43%)
XOMAO : 25.20 (-0.40%)

Business Summary

XOMA ROYALTY is a biotechnology royalty aggregator. The company acquires the potential future economics associated with pre-commercial therapeutic candidates which have been licensed to pharmaceutical or biotechnology companies. XOMA ROYALTY, formerly known as XOMA Corporation, is based in EMERYVILLE,...

See More

Key Turning Points

3rd Resistance Point 21.44
2nd Resistance Point 20.91
1st Resistance Point 20.44
Last Price 19.97
1st Support Level 19.44
2nd Support Level 18.91
3rd Support Level 18.44

See More

52-Week High 35.00
Fibonacci 61.8% 28.64
Fibonacci 50% 26.68
Fibonacci 38.2% 24.71
Last Price 19.97
52-Week Low 18.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar